Arava is a brand-name medication that contains the active ingredient leflunomide. It is supplied as oral pills in strengths of 10 mg and 20 mg. Leflunomide belongs to the class of disease-modifying anti-rheumatic drugs (DMARDs) and is used in the management of autoimmune conditions. In Hong Kong, Arava is a prescription-only product regulated by the Department of Health and the Pharmacy and Poisons Board.
Leflunomide inhibits the enzyme dihydroorotate dehydrogenase (DHODH), which is essential for de novo synthesis of pyrimidine nucleotides. By blocking this pathway, the drug reduces the proliferation of activated T-lymphocytes and B-lymphocytes, key players in the inflammatory response of autoimmune diseases. The effect becomes apparent within a few weeks, with peak clinical benefit typically reached after several months of continuous therapy. Oral absorption is rapid; the active metabolite, teriflunomide, has a long half-life, contributing to sustained immunomodulation.
These indications are based on clinical trial evidence demonstrating reductions in joint tenderness, swelling, and disease activity scores.
Disclaimer: Off-label use requires close medical supervision and individualized risk assessment.
Patients should inform their healthcare provider of all prescription medicines, over-the-counter products, dietary supplements, and herbal preparations before initiating Arava.
Dosing must be individualized by a qualified healthcare professional.
Regular clinical review of disease activity (joint counts, symptom scores) is advised to assess therapeutic response and adjust therapy as needed.
This article provides educational information about Arava and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Arava can be combined with methotrexate in patients who need stronger disease control, but the combination increases the risk of liver toxicity and bone marrow suppression. Close laboratory monitoring is essential, and the regimen should be prescribed by a rheumatologist familiar with both agents.
If you remember within 12 hours, take the missed tablet. If it is later than 12 hours before the next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two tablets at once.
Yes. Baseline liver function tests, complete blood count, and renal function should be obtained before the first dose to ensure the medication can be used safely.
Clinical benefits often become noticeable after 4-6 weeks of consistent therapy, with maximum effect typically reached after several months of treatment.
Arava is a prescription medication; carry it in its original labeled container with a copy of the prescription. Check the destination country’s medication import regulations, and be prepared for security screening.
Not all patients experience liver enzyme elevations, but routine monitoring is recommended because hepatotoxicity is a recognized risk. Prompt reporting of symptoms such as jaundice or dark urine is important.
Warning signs include yellowing of the skin or eyes, persistent nausea or vomiting, abdominal pain, and unusually dark urine. Seek immediate medical attention if any of these occur.
Moderate alcohol consumption may be acceptable, but excessive intake can increase the risk of liver damage. Discuss your drinking habits with your prescriber to determine a safe limit.
Arava is an oral conventional DMARD, whereas biologics are injectable agents targeting specific inflammatory pathways. Choice of therapy depends on disease severity, prior treatment response, comorbidities, and patient preference.
Effective barrier methods (e.g., condoms) combined with hormonal contraception (e.g., oral pills, IUD) are recommended. Because leflunomide remains in the body for an extended period, reliable contraception must be maintained throughout treatment and for at least two years after discontinuation.
